HCW Biologics Inc is trading at $1.27 (-12.41%) after the company filed a resale registration for up to 5.7 million shares linked to a recent private placement.
- The filing has increased investor concerns regarding dilution and share overhang risk, which typically pressures microcap biotech valuations.
- This downward move follows a period of heavy recent weakness for the stock as the market reacts to the potential for increased share supply.